Supernus Pharmaceuticals (SUPN) Getting Somewhat Positive News Coverage, Analysis Finds
News stories about Supernus Pharmaceuticals (NASDAQ:SUPN) have trended somewhat positive on Wednesday, Accern reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Supernus Pharmaceuticals earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 46.112300229185 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Supernus Pharmaceuticals Inc (SUPN) Moves 1.25% – Evergreen Caller (evergreencaller.com)
- Supernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Quarterly Sales of $77.74 Million (americanbankingnews.com)
- Supernus Pharmaceuticals Inc (SUPN) Ichimoku Reveals Positive Momentum – Financial News Review (finnewsreview.com)
- Brokerages Expect Supernus Pharmaceuticals Inc (SUPN) Will Announce Earnings of $0.27 Per Share (americanbankingnews.com)
- Express Scripts Holding Company (ESRX) registers a price change of 2.14% while Supernus Pharmaceuticals, Inc … – Stocks Gallery (stocksgallery.com)
Several analysts have recently commented on SUPN shares. Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective for the company in a research note on Thursday, July 13th. Cantor Fitzgerald increased their price objective on Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a research note on Wednesday, July 5th. Jefferies Group LLC increased their price objective on Supernus Pharmaceuticals from $45.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, June 28th. Stifel Nicolaus reissued a “buy” rating and issued a $47.00 price objective (up from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Finally, BidaskClub downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $48.43.
Shares of Supernus Pharmaceuticals (NASDAQ SUPN) opened at 43.75 on Wednesday. The company’s 50 day moving average price is $42.82 and its 200-day moving average price is $35.43. The stock has a market capitalization of $2.22 billion, a P/E ratio of 22.07 and a beta of 1.31. Supernus Pharmaceuticals has a 12 month low of $17.25 and a 12 month high of $46.55.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.08. The company had revenue of $75.83 million during the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. Equities analysts predict that Supernus Pharmaceuticals will post $1.04 earnings per share for the current year.
In other news, VP Padmanabh P. Bhatt sold 10,000 shares of Supernus Pharmaceuticals stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $39.86, for a total transaction of $398,600.00. Following the completion of the sale, the vice president now directly owns 27,500 shares in the company, valued at $1,096,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Padmanabh P. Bhatt sold 2,556 shares of Supernus Pharmaceuticals stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $44.90, for a total transaction of $114,764.40. Following the sale, the vice president now owns 24,944 shares of the company’s stock, valued at $1,119,985.60. The disclosure for this sale can be found here. Insiders have sold 20,000 shares of company stock valued at $848,824 over the last quarter. Insiders own 6.70% of the company’s stock.
WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/supernus-pharmaceuticals-supn-getting-somewhat-positive-news-coverage-analysis-finds/1531785.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.